Browse the evidence

Genetically proxied activation of the glucagon-like peptide-1 receptor (GLP1RA) is causally associated with a reduced risk of schizophrenia.

This study suggests that medications activating the GLP-1 receptor (like semaglutide or liraglutide) may lower the risk of developing schizophrenia, primarily through their effect on body weight. For individuals at high risk of schizophrenia who are overweight, using these medications for weight management might offer a dual benefit of metabolic health and reduced psychiatric risk. However, this is based on genetic data, not direct clinical trials, so it should not replace standard psychiatric care.

Non-sulfated CCK peptides stimulate gastric acid secretion via CCK2 receptors, acting similarly to gastrin, whereas sulfated CCK inhibits acid secretion via CCK1 receptors.

The form of CCK matters. In rare tumors (CCKoma), non-sulfated CCK can cause ulcers by stimulating acid. In healthy individuals, sulfated CCK inhibits acid. This distinction is crucial for understanding gastric pathologies.

Higher genetically predicted BMI does not increase the risk of cancer mortality.

While higher BMI increases risks for other causes of death, this study did not find a link to cancer mortality.

Twelve weeks of dapiglutide (4 mg or 6 mg) once weekly does not produce a statistically significant reduction in body weight compared to placebo in adults with obesity.

In this study, taking 4 mg or 6 mg of dapiglutide once weekly for 12 weeks did not lead to significant weight loss compared to a placebo in people with obesity. The drug was safe, but the dose might be too low or the treatment period too short to see results. Future studies may need higher doses or longer durations.

Emergency department exposures to GLP-1 and GLP-1/GIP receptor agonists predominantly result in mild, self-limiting gastrointestinal symptoms (nausea, vomiting) that typically resolve within 8 to 24 hours with supportive care.

If you or someone else takes too much of a GLP-1 medication (like Ozempic or Wegovy), expect nausea and vomiting. These symptoms are usually mild and go away within a day. Focus on hydration and rest. Seek medical help if you feel faint, have severe abdominal pain, or cannot keep fluids down.

YouTube videos on semaglutide (Ozempic/Wegovy) largely fail to adequately communicate critical safety risks, specifically the risk of aspiration during anesthesia, the persistence of side effects due to the drug's long half-life, the risk of counterfeit drugs, and the lack of long-term data.

Do not rely on YouTube videos for safety information about semaglutide. They often miss critical risks like aspiration during surgery, the persistence of side effects due to the drug's long half-life, and the danger of counterfeit products. Always consult a physician for personalized advice and safety monitoring.

Adjunctive semaglutide therapy significantly enhances total body weight loss and prevents post-balloon weight regain compared to intragastric balloon (IGB) alone in patients with BMI ≥ 27 kg/m².

If you are using an intragastric balloon for weight loss, adding semaglutide (a GLP-1 medication) can significantly increase your total weight loss and help you keep the weight off after the balloon is removed. The study used a specific dosing schedule starting at 0.5mg and going up to 1mg weekly, pausing while the balloon is in place, and restarting after removal. This approach helps overcome the natural weight regain that often happens after balloon removal alone.

In patients with overweight or obesity without type 2 diabetes, 1-year treatment with semaglutide 2.4 mg or tirzepatide results in clinically meaningful weight loss of 14.1% and 16.5%, respectively, in real-world clinical practice.

If you have obesity or are overweight and do not have type 2 diabetes, treatment with semaglutide (Wegovy) or tirzepatide (Zepbound/Mounjaro) for one year in a real-world setting leads to significant weight loss, averaging 14-16% of body weight. This effectiveness holds true in routine clinical practice, not just in clinical trials, although reaching the maximum dose is not guaranteed for everyone.

Adjuvant semaglutide at lower doses (≤1 mg/week) achieves clinically significant weight loss (median 7.5% TWL) in post-bariatric surgery patients with refractory obesity, with a favorable side effect profile compared to higher doses.

If you have had bariatric surgery and are experiencing weight regain or insufficient loss, ask your doctor about adjuvant semaglutide. You may not need the highest dose (2.4 mg); many patients achieve significant weight loss (around 7.5% of total body weight) at lower doses (1 mg or less). This approach is often more affordable, has fewer side effects, and is sufficient for long-term management, especially if supply of higher doses is an issue.

Post-bariatric patients with insufficient weight loss or weight regain achieve significant additional weight loss and comorbidity improvement when treated with GLP-1 receptor agonists (semaglutide or dulaglutide).

If you have had bariatric surgery and are not losing enough weight or are gaining it back, ask your doctor about GLP-1 medications like semaglutide or dulaglutide. These drugs can help you lose more weight and improve health conditions like high blood pressure and sleep apnea. They are taken as weekly injections and are generally well-tolerated, though nausea is a common side effect.

Subcutaneous semaglutide (starting 0.25 mg, titrated to 1 mg weekly) significantly reduces body weight and HbA1c in patients with type 2 diabetes, with maximal efficacy observed when combined with lifestyle modifications (diet and exercise).

If you have Type 2 Diabetes, semaglutide (Ozempic) is an effective tool for losing weight and lowering blood sugar. To get the best results, take it as prescribed (starting low and building up) and combine it with a healthy diet and regular exercise. Be aware that stomach issues like nausea are common reasons people stop taking it, so talk to your doctor about managing these side effects to stay on the medication.

Semaglutide (both injectable and oral formulations) induces significant weight loss and maintains weight loss over 12-24 months in patients with type 2 diabetes and obesity/overweight.

If you have type 2 diabetes and are overweight or obese, semaglutide (either as a weekly injection or daily pill) can help you lose a significant amount of weight and keep it off for at least a year. It works best when combined with a moderate calorie-reduced diet and regular walking. Both forms are effective, so you can choose based on your preference for injections vs. pills.

Higher dietary protein intake is significantly associated with higher Phase Angle (PhA) in athletes, independent of fat-free mass, sex, and age.

If you are an athlete, ensure your daily protein intake is sufficient (likely >1.2 g/kg/day, with higher intakes up to ~1.8-2.1 g/kg/day potentially offering higher Phase Angle benefits). Focus on high-quality protein sources like meat and eggs, as these were specifically linked to better Phase Angle values independent of total calories or muscle mass. This suggests that optimizing protein intake supports cellular health and muscle integrity, which can be monitored via Phase Angle.

CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, produces clinically meaningful weight loss (4.7% to 8.0% over 4 weeks) and improved glycemic control in participants with overweight or obesity, with a safety profile consistent with other incretin-based therapies.

CT-388 is a once-weekly injection that helps people with overweight or obesity lose weight (4.7% to 8.0% in 4 weeks) and improves blood sugar control. It is generally well-tolerated, with most side effects being mild or moderate. This makes it a promising option for treating obesity and type 2 diabetes, though long-term data is still needed.

GZR18, a GLP-1 receptor agonist administered once-weekly or bi-weekly, induces robust body weight reductions (up to 17.8%) and improves metabolic parameters in Chinese adults with overweight or obesity.

GZR18 is a once-weekly or bi-weekly GLP-1 injection that helps overweight or obese Chinese adults lose significant weight (up to 17.8%) and improve metabolic health. It is designed to minimize side effects like nausea, making it a potentially tolerable option for those who struggle with frequent injections or severe gastrointestinal issues from other GLP-1 drugs. Consult a doctor to see if it's appropriate for you.

A structured, virtual, community-based lifestyle intervention using meal replacements and behavioral support achieves weight loss (14-16%) and type 2 diabetes remission (43%) comparable to GLP-1 receptor agonist therapies.

To achieve significant weight loss and potentially reverse type 2 diabetes, consider a structured program that combines a temporary period of meal replacements with long-term behavioral support. Look for programs that offer frequent check-ins, community support, and a clear plan for transitioning back to regular food. This approach can be as effective as newer weight-loss drugs for many people, especially when sustained over 18 months.

AI-powered virtual health coaches (e.g., chatbots like Paola) combined with wearables can significantly improve physical activity, dietary adherence, and reduce weight and waist circumference in inactive adults aged 45-75.

For adults over 45 who are inactive, using an AI-powered health app with a wearable tracker can significantly boost physical activity and improve diet. Look for programs that offer a chatbot for guidance and track your activity automatically. This approach can lead to modest but meaningful weight loss and waist reduction without needing intensive in-person counseling.

Tirzepatide administered at low doses (≤10 mg) for 6 months produces clinically meaningful weight reduction (mean 11.9%) in non-diabetic adults, achieving outcomes comparable to higher doses used in clinical trials.

If you are starting tirzepatide for weight loss without diabetes, you do not need to reach the maximum dose to see significant results. In real-world use, staying on lower doses (like 5mg) for 6 months still resulted in an average 11.9% body weight reduction, which is clinically meaningful.

Real-world use of semaglutide for weight loss (SEMA-WL) in adults with obesity results in median weight loss of 17% after >5 months of treatment, with nausea and constipation being the most common side effects.

If you have obesity and are considering semaglutide, expect significant weight loss (around 17% after 5+ months) but also common side effects like nausea and constipation. Most users find self-injection manageable, though some prefer a pill. Talk to your doctor about managing side effects and setting realistic expectations.

Personalized Behavioral Weight Loss (PBWL) optimizers (those who achieve ≥5% weight loss) lose significantly more weight than Standard BWL optimizers, suggesting personalization maximizes potential for responders.

If you are a 'responder' to weight loss interventions, personalizing your diet and activity based on your body's feedback (like glucose response) can nearly double your weight loss compared to standard advice. Find your 'best fit' prescription early.

High digital engagement (defined as attending ≥1 coaching session, logging weight ≥4 times/month, and using app features) significantly enhances weight loss efficacy and accelerates milestone achievement in patients treated with dual GIP/GLP-1RA or GLP-1RA, without increasing safety risks.

To get the most out of your GLP-1 or dual GIP/GLP-1RA medication, actively use the digital support tools provided. This means attending at least one coaching session, logging your weight at least four times a month, and interacting with the app's educational features. This level of engagement is associated with losing 4.5% more body weight and reaching your weight loss goals faster, without increasing your risk of side effects. Treat these digital tools as essential parts of your treatment, not optional extras.

High-Intensity Interval Training (HIIT) performed for 7 weeks leads to significant long-term reductions in body mass, fat mass, and visceral fat area in women with overweight/obesity, even two years after the intervention ends, whereas Time-Restricted Eating (TRE) alone does not significantly reduce these metrics compared to baseline in the long term.

For women with overweight or obesity, incorporating High-Intensity Interval Training (HIIT) into your routine, even just 3 times a week, can lead to significant, lasting reductions in body fat and visceral fat, even two years after you stop supervised training. While Time-Restricted Eating helps with habit formation, it may not be enough on its own for significant fat loss; combining it with HIIT or focusing on HIIT yields better long-term body composition results.

Survodutide, a dual glucagon and GLP-1 receptor agonist, induces significant weight loss in adults with obesity without type 2 diabetes when administered as a once-weekly subcutaneous injection up-titrated to 3.6 or 6.0 mg alongside lifestyle modifications.

This treatment involves a weekly injection that mimics two natural hormones (GLP-1 and glucagon) to reduce appetite and increase energy burn. It is prescribed for adults with obesity who do not have diabetes. To maximize results, patients must follow a reduced-calorie diet and exercise regularly. The dose starts low and increases slowly to minimize stomach upset, which is a common side effect.

Personalized nutrition significantly reduces HbA1c levels compared to standard control diets in adults with type 2 diabetes or prediabetes, with a median mean difference of -0.925%.

For adults with type 2 diabetes or prediabetes, using personalized nutrition strategies that incorporate individual biological data (like gut microbiome or genetic markers) alongside clinical metrics can lead to greater reductions in HbA1c compared to standard dietary advice. While the evidence quality is currently low due to study variability, the approach shows promise for improving glycemic control.